Q J Med 2001; 94: 575-597
© 2001 Association of Physicians
Review |
Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?
1 From the University of Sheffield Medical School, Sheffield, 2 University of Aberdeen, Aberdeen, 3 University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, 4 University of Southampton, Southampton, 5 Guy's Hospital, London, 6 Freeman Hospital, Newcastle upon Tyne, 7 The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, and the Royal Shrewsbury Hospital, Shrewsbury, 8 Nottingham City Hospital, Nottingham, 9 Hull Royal Infirmary, Hull, and 10 Imperial College of Science, Technology and Medicine, London, UK
 |
Summary |
|---|
 Top Summary IntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
The burden of non-vertebral fractures is enormous. Hip fractures account for nearly 10% of all fractures (and a much greater proportion in the elderly), while wrist fractures may account for up to 23% of all limb fractures. The best available predictors of non-vertebral fracture risk are low BMD and a tendency to fall. Hip, forearm, proximal humerus and rib fractures have all been associated with low BMD, though ankle fracture is not strongly related to osteoporosis. Although clinical risk factors identify only about one-third of postmenopausal women at increased risk of osteoporotic fracture, the occurrence of one fracture commonly predicts a second fracture. Guidelines are presented for identifying and treating patients at risk of non-vertebral osteoporotic fractures, especially those with a previous fracture, based on the algorithm recently published by the Royal College of Physicians and the Bone and Tooth Society. Prevention of falls and use of external hip protectors may reduce the occurrence of hip fracture. Treatment options for patients presenting with hip fracture include HRT, bisphosphonates, and calcium plus vitamin D, and for Colles' fracture include general measures, HRT, bisphosphonates, or calcitonin plus calcium.
|
Introduction |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
The burden of non-vertebral fractures on the National Health Service is enormous. Hip fractures alone account for nearly 10% of all fractures, and for a much higher proportion in the elderly.1 However, most orthopaedic surgeons do not see the need to investigate or treat osteoporosis in patients presenting with hip fracture.2 Over 180 000 osteoporosis-related fractures occur each year in the UK, of which about 70 000 are hip fractures, 25 000 are symptomatic vertebral fractures, and 41 000 are wrist fractures.3 The direct cost (health plus social services) to the nation of these osteoporotic fractures is estimated as £1.7 billion/year, with hip fractures accounting for the greater part.4 The total cost of a hip fracture in the UK has been estimated as £12 000–20 000.3,4 Hospital resources are used to a disproportionate extent by patients with hip fractures. In a series in Rochester, Minnesota, hip fractures accounted for only 7% of all fractures, but for nearly 29% of those hospitalized and for 52% of hospital bed-days used.5 In contrast, fractures of the radius and ulna accounted for 27% of all fractures, but only for 8% of hospital bed-days. Targeting therapy to patients at high risk of sustaining hip fracture in particular, but also other non-vertebral fractures that may increase the risk of hip or other fractures, may provide substantial costs savings and improve patient management.
Decreased BMD at various skeletal sites has been associated with the occurrence of vertebral, hip and wrist fracture in many studies,6–11 and evidence is beginning to accumulate that other fractures, e.g. humerus and rib fractures, may be related to osteoporosis. In view of this evidence, a UK Consensus Group recently reviewed the literature on non-vertebral osteoporosis-related fractures. This was not a systematic review, but all relevant English-language articles on issues relating to patients with non-vertebral fractures were identified and discussed by the group of experts, followed by a further discussion meeting to review the draft manuscript. The aim was to identify the risk factors for non-vertebral fractures, and specifically when such fractures should be considered as the trigger for initiating secondary prevention of osteoporosis, in order to improve the overall management of osteoporosis-related fractures. Adequate follow-up is particularly important for patients with these fractures, who are at risk of future fractures, but may only present to orthopaedic or fracture clinics.
|
Epidemiology of fracture |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Hip fracture
In the West, the incidence of hip fracture rises exponentially with advancing age in men and women over 75-years-old (Figure 1). 1 Overall, in the UK, hip fractures may account for up to 9% of all limb fractures (4% of fractures in men and 15% in women) (Table 1).1,12 In African populations, however, no marked increase in the incidence of hip fracture with increasing age up to 74 years was found in either men or women.13
|
|
Regional variations in the incidence of hip fracture in the UK have been noted,14 and rates also vary between countries.13,15–17 A low incidence of osteoporotic fractures in West Africa is observed despite low BMD being common.18 Seasonal variations in the incidence of hip fracture have been reported in both northern and southern temperate regions of the world,19 possibly related to lower levels of vitamin D in winter.
Wrist fracture
The lifetime risk of a fracture of the lower end of the radius and ulna is 16% for women, and this makes it as common as hip fracture.20 Overall, such fractures account for about 23% of all limb fractures in the UK (18% of fractures in men and 30% in women) (Table 1).1 The incidence of wrist fractures peaks during childhood, then declines before rising steadily from age 45 years in women but not in men (Figure 1).1 Over the last 50 years, the incidence of forearm fractures in children has increased, though the reason for this is unclear.21
The incidence of wrist fracture also varies with geographical location13,22 in a pattern similar to that for hip fracture but different from that reported for vertebral deformity, for which prevalence rates are more similar.23 Seasonal variations in the incidence of Colles' fracture have been reported.19,24
Other fractures
Less epidemiological information is available than for hip, vertebral and wrist fractures, but fractures of the foot, ankle, humerus, ribs, pelvis, hand and clavicle generally appear to be more common in elderly White Caucasians, particularly women, than in Black populations.25 Fractures in the elderly tend to occur at the ends of the long bones, particularly at the proximal ends,25 and are mainly associated with moderate trauma.25 Fractures of the proximal humerus show a marked age-related increase in incidence in White women, particularly after the age of 65 years (Figure 2).26 Fractures of the shaft and distal humerus are less common than proximal fractures, but show similar trends. The incidence of fractures of the ankle and foot, however, which are often regarded as osteoporosis-related, show no age-related increase after mid-life. In the axial skeleton, the incidence of pelvic fractures showed an exponential increase after age 75 years, but was lower than for hip fracture. After age 55 years, 75% of pelvic fractures were associated with moderate trauma. Fractures of the clavicle and scapula gradually increased in incidence to mid-life and then steadily declined; these fractures tend to be associated with moderate or severe trauma. Fractures of the ribs and sternum had a relatively high incidence, and showed a gentle increase in the elderly.
|
In a longitudinal study in White Caucasian subjects aged >60 years, non-hip fractures accounted for 90% of total fractures up to age 80 years, and after 80 years accounted for 59%.27 Rib fractures and humerus fractures were more common than previously thought (300/100 000 woman years and 400/100 000 woman years, respectively) compared with distal radial fracture (600/100 000 woman years) and hip fracture (700/100 000 woman years) in the same group. Focusing on hip fractures may thus underestimate the resource implications of osteoporosis. This incidence of humerus fractures, however, is higher than that reported elsewhere in the UK (annual incidence of 70/100 000 population for all humerus fractures).1 A study based on Accident and Emergency admissions has also indicated that non-hip fractures account for over 90% of all fractures.12 The overall annual incidence of non-hip fractures in this study was 1964/100 000, which is substantially greater than previously reported.1
Increasing trends in fracture rates
The incidence rates and absolute numbers of vertebral, hip and limb fractures appear to be increasing in Western populations. This may be partly due to an increase in the proportion of elderly people, but also arises from a pronounced increase in the age-adjusted incidence, particularly in the population >75-years-old, after 1980/1981.28 In the same study, the age-specific incidence of vertebral fractures in the elderly showed a steady increase after age 60–69 years in 1982/1983 that had not been evident in the early 1950s. Between 1950/1954 and 1983, the prevalence of vertebral fracture in normal lateral chest radiographs increased about fivefold.28 In women, the incidences of fragility fractures of the distal radius, proximal humerus, ankle, tibial condyle and patella increased between the 1950s and the 1980s, particularly in women over 55–60-years-old. This increasing trend seems to have continued for fractures of the proximal humerus in elderly people up to 1993.29 Age-adjusted hip fracture rates in the UK and USA rose through earlier decades of this century, but appear to have now reached a plateau;30,31 numbers of fractures continue to increase because of the ageing of the population.
Morbidity and mortality of hip fracture32,33
At 1 year after a hip fracture, about 40% of patients are unable to walk independently, 60% are limited in at least one class 1 activity of daily living (e.g. feeding, dressing, toileting), and 80% are limited in a class 2 activity of daily living (e.g. shopping, gardening, climbing stairs). In the first year, about 27% of hip fracture patients will require nursing home care; after 1 year this figure falls to 14%, though 30% will still require home support. Of the patients who were independent before a hip fracture, 18% become dependent and 8% require nursing home care. Life expectancy is reduced by hip fracture, and this increase in mortality is greater in older women than in younger women.34 Mortality in men is greater than in women at all ages over 50 years.35 This excess mortality is restricted to patients with reduced mental status, reduced somatic health and low physical ability.36
The epidemiology of non-vertebral fractures is summarized in Table 2.
|
|
Risk factors for fracture |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
To avoid the development of osteoporosis-related fractures in later life, it is particularly important to identify perimenopausal or early postmenopausal women at increased risk of such fractures. Several factors contribute to the development of osteoporosis-related fractures, including bone mineral density (BMD), bone architecture, and other factors associated with physical frailty and an increased risk of falls. The best available predictor is BMD,37 but methods of measurement are expensive and not always available. Attempts to identify clinical predictors have met with only limited success, and in general clinical risk factors are poor at predicting low BMD38,39 or fractures. Only about 17–27% of postmenopausal women at risk of hip fracture, 18–35% of those at risk of vertebral fracture, and 37–47% of those at risk of radial fracture because of low BMD are identified by assessing clinical risk factors.40–45 The clinical risk factors that have been associated with a small increase in the risk of hip fractures include excess caffeine (but not tea), age, benzodiazepines, falls in the previous year, being on the feet for <4 h/day, maternal hip fractures, inability to rise from a chair, current smoking, and anticonvulsants.46 It appears that no single factor is responsible for the pathogenesis of osteoporosis-related fractures, but a combination of factors, which may differ between individuals.
BMD as a predictor
BMD is determined by several factors, including peak bone mass, genetic influences and environmental factors, in addition to disease states.47–50
Hip fracture and BMD
In patients with hip fracture, BMD is low in the hip, radius, and lumbar spine, and calcaneus.51,52 Hip fractures, particularly intertrochanteric fractures, have also been associated with low bone mass measured by quantitative ultrasonography.9,53,54 Women over 65 years of age with hip BMD in the lowest quartile had an 8.5-fold greater risk of hip fracture than those in the highest quartile, and low hip BMD was a stronger predictor of hip fracture than BMD at other sites.7 A low hip BMD in a patient with hip fracture increases the risk of subsequent hip fracture.55
Forearm fracture and BMD
In most studies, BMD of the non-fractured forearm was decreased in patients with forearm fractures,37,56–64 although there have been exceptions.11,65,66 Most forearm fractures occur about 2.5 cm from the radial styloid, in the ultradistal radius, where at least two-thirds of the bone is cancellous and less than one-third is cortical.61 In 119 normal women aged 30–75 years and 40 women aged 53–80 years with women Colles' fracture, the risk of Colles' fracture rose sharply as ultradistal radial BMD fell below 0.4 g/cm2 (Figure 3).61 The association was at least as strong between forearm ultradistal BMD and forearm fracture as it was between lumbar spine BMD and vertebral fracture6 and between hip BMD and hip fracture.7 In a prospective study, the incidence of distal forearm fractures was 4.1 times greater and that of proximal humerus fracture 7.5 times greater in women in the lowest quintile of distal radial BMD compared with those in the highest quintile.67 Forearm BMD does not decrease with age in men,68 nor does the incidence of forearm fracture increase.19
|
Spinal BMD is 5–7% lower in women following a Colles' fracture,6,64,65,69–71 although this lowering is less than in the ultradistal radius in these patients (Figure 4).6 Low spinal BMD could result from a low BMD at the time of the menopause72 and/or from an increased rate of bone loss,73 but this latter finding has not been confirmed.74,75 In a series of 1288 men and women with distal forearm fracture, there was a fivefold increase in risk among women and a 10-fold increase among men in the risk of vertebral fracture.76
|
Colles' fracture is also associated with a 1–8% lower hip BMD,63,64,71,77 although a recent study has suggested that in women over 65 years of age, hip BMD following Colles' fracture was not lower than the age-matched normal value.11 The risk of hip fracture following Colles' fracture is higher in older people.78
In a study of postmenopausal women with vertebral, Colles', or both fractures, ultradistal radial BMD was a significantly better indicator of Colles' fracture than spinal BMD; the converse was also true.6 Colles' fractures tend to occur in postmenopausal women with low metacarpal BMD10 and in women under 65-years-old with low hip BMD.11 In a meta-analysis of prospective cohort studies with about 90 000 person years of observation and over 2000 fractures, the relative risk of forearm fracture was 1.7–1.8 for each decrease of 1 SD in BMD at that site, compared with a relative risk of 2.6 for hip fracture with each 1 SD decrease in hip BMD.51 The predictive ability of a decrease of 1 SD in BMD was similar to (or for hip and spine measurements better than) that of a 1 SD increase in blood pressure for stroke and better than a 1 SD increase in serum cholesterol level for cardiovascular disease.79
Predictions of the incidence of Colles' fracture in the general population based on BMD alone are very close to the observed incidence,80 which suggests that in addition to falling, low BMD is a major determinant of Colles' fracture, and that Colles' fracture is strongly related to osteoporosis. In particular, it is a useful indicator of an increased risk of hip fracture, in addition to an increased risk of vertebral fracture. Colles' fracture occurs relatively commonly, and is a diagnosis that is unlikely to be missed.
BMD and other fractures
Fractures of the foot, ankle, humerus, ribs, pelvis, hand and clavicle have all been related to low BMD. In a retrospective study of 621 patients, foot and rib fractures were associated with low femoral neck BMD, though BMD at both the lumbar spine and the femoral neck was normal in subjects who had suffered ankle fractures.81 In another retrospective study of 3222 women (mostly postmenopausal), earlier fractures of the rib, ankle, clavicle and patella were related to reduced spinal BMD, and fractures of the clavicle, tibia, patella and foot were related to reduced femoral neck BMD.82 This study is difficult to interpret, however, because most of the fractures occurred when the women were premenopausal. In the prospective Study of Osteoporotic Fractures, which enrolled 9704 patients over 65 years old, the incidence of most fracture types (including wrist, foot, humerus, hip, rib, toe, leg, hand, pelvis and clavicle, but excluding ankle, elbow, fingers and face) was significantly increased in elderly women with low BMD at the distal or proximal radius, or the calcaneus.83 In a follow-up study, neither ankle nor foot fractures were related to age or to femoral neck or lumbar spine BMD, though they were related to low distal radial BMD.84 Other studies have shown that ankle fracture is related to significantly increased weight and body mass index, but is largely independent of low bone mass.84
The body of evidence does not, therefore, support the view that ankle fracture is strongly related to osteoporosis. Of fractures other than vertebral, hip or wrist, fractures of the humerus, rib and pelvis are the most likely to be related to osteoporosis. Fracture of the humerus is potentially the most useful indicator, being related to low BMD and showing a marked age-related increase in women over 65 years old.25 It also occurs relatively commonly and is a diagnosis that is unlikely to be missed. Although the incidence of rib fracture increases in the elderly,25 and it is at least as common as proximal humerus fracture with increasing age,27 patients often tolerate a rib fracture without seeking medical attention. When a patient with a low or moderate trauma rib fracture does present, however, osteoporosis should be considered.
Bone architecture
Bone structure is related to bone composition and turnover, skeletal geometry and body habitus. The femoral neck and the mid-shaft radius consist predominantly of cortical bone, whereas the distal radius and vertebrae are mainly cancellous in content.6,85 The proximal humerus is mainly metaphyseal bone, which is predominantly cancellous, while the ribs are mainly diaphyseal bone, which is predominantly cortical.
Changes in bone composition have been linked with osteoporosis.86,87 With increasing age, marked loss of osteocytes in the femoral head occurs without any change in vertebral osteocyte numbers, and this bone death may contribute to hip fracture in the elderly,88 though it is similar in cases of hip fracture and age-matched controls.89 The connectivity of osteoporotic cancellous bone, which reflects its strength, is also significantly decreased compared with normal bone, independently of bone volume.90 Differences in connectivity have been linked with ethnic differences in fracture rates.91 Bone turnover may be lower in Black subjects, which may increase trabecular strength,92 though this is not a universal finding.91 The Black femoral neck, though not the shaft, has a distribution of bone which gives it intrinsically greater strength.93 The geometric characteristics of bone have been implicated in the risk of hip fracture. The risk of osteoporotic hip fractures is significantly higher in White women than in Asian or Black women, who have a significantly shorter hip axis length.94 Hip axis length was also significantly longer in women with osteoporosis and hip fracture than in those with osteoporosis and vertebral fracture, though femoral neck BMD was reduced to a similar extent below control values in both groups.95 This probably reflects differences in mechanical loading, with a shorter femoral neck intrinsically stronger and less susceptible to fracture. Hip strength analysis may provide a better prediction of recent contralateral hip fracture than conventional BMD,96 even though as subjects grow older their apparent hip strength may fall less rapidly than BMD due to apparent expansion of the periosteal envelope.97,98 Hip axis length may have been growing over recent generations in White patients.99,100
Falls and muscle strength
The considerable increase in incidence of wrist fractures in perimenopausal women has been related to the increasing incidence of falls in these women.101 In contrast, the risk of falling does not increase in middle-aged men, which is reflected in the stable incidence of wrist fractures in men throughout life. The incidence of falls increases in the elderly in both sexes, but is generally lower in men than in women. Falling is the major cause of a first hip fracture in women, and an increased incidence of falling also increases the risk of a second hip fracture.102 Muscle weakness, postural instability (e.g. in menopausal women60) and incoordination, and possibly drug treatment (e.g. with long-acting benzodiazepines or anticonvulsants) all increase the risk of falling, and as a result increase the risk of hip fracture.46 In a case-controlled study, other risk factors for falls in women with hip fracture included lower limb dysfunction, visual impairment, previous stroke disease and Parkinson's disease,103 and these medical conditions are associated with increased risk of contralateral hip fracture.104
In a comprehensive study of over 8000 women >65-years-old who suffered 203 hip fractures and 321 wrist fractures during 4.1 years of follow-up, the nature of the fall determined the type of fracture.105 Whether a fracture actually occurred when the faller landed on a particular bone, however, was determined by BMD and factors that attenuated the force of impact of the fall. For direct falls on the hip, the odds ratio for the risk of hip fracture was 32.5, while for falls on the hand or wrist, the odds ratio for wrist fracture was 20.4. This suggests that one approach to prevention of these fractures may be modification of the trauma, e.g. hip protection devices. In women who had one or more falls in the year before baseline, the relative risk of Colles' fracture was 1.31; good visual acuity, which reduces the risk of falling, reduced the relative risk of distal forearm fracture to 0.83.67 Ankle fractures have also been associated with a history of falls.84
The importance of muscle strength is indicated by a study of 3270 healthy elderly women, in whom the risk of hip and other non-vertebral fractures was reduced significantly by giving calcium and vitamin D.106 The reduction became evident within 6 months, and was probably due to reversal of secondary hyperparathyroidism and an increase in muscle strength. Physical activity and muscle strength both protect against hip fracture, and the risk of fracture is lower in subjects with greater grip strength (which correlates with activity).107 Decreased quadriceps strength and postural instability may increase the risk of osteoporosis-related fracture.108
Previous fracture
The risk of hip fracture is increased by a previous fracture. In patients over 35-years-old, the relative risk of hip fracture increased significantly and almost immediately following a Colles' fracture, the increase being most marked in men (Table 3).78 The odds ratio of hip fracture was increased by 2.3 in men and women with a previous wrist fracture.107 In women >60-years-old, fractures of the lumbar spine, olecranon, knee or ankle increased the risk of a subsequent hip fracture, but this increased risk tended to level off 3 years after the primary fracture.109 In a retrospective, population-based cohort study, the risk of hip fracture following an index forearm fracture was increased 1.4-fold in women and 2.7-fold in men, and the risk of subsequent vertebral fracture increased 5.2-fold in women and 10.7-fold in men.76 A previous hip fracture also increased the odds ratio of a later, second hip fracture by 6–8-fold,107,110,111 though second hip fractures usually occur in the contralateral side.112 A previous spine fracture increases the risk of a subsequent hip fracture 2.4-fold.113
|
The risk of wrist fracture may also be increased by a previous fracture. Women who had sustained a fracture at any site since the age of 50 years had a slightly increased risk (relative risk 1.26) of suffering a Colles' fracture, as did women who had one or more falls in the year before baseline (relative risk 1.31).67 Women with vertebral fractures also have an increased incidence of forearm fractures.114
An overview of the risk factors for non-vertebral fractures is presented in Table 4.
|
|
Bone turnover and calcium metabolism in patients with fracture |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Bone turnover in hip fracture
BMD may continue to decrease after hip fracture, by 4–5% at the uninjured hip in the first year, putting the patient at greater risk of a subsequent fracture.114,115 The loss in BMD at the femoral neck in the year after hip fracture may be five times that reported for the non-fractured population.116–118 In elderly patients with hip fracture, there was a 2.4% loss of BMD from the lumbar spine in the first year, and this correlated with 1,25-dihydroxy vitamin D status; the percentage loss of BMD was greatest in patients with a higher baseline BMD, reaching nearly 5% in those whose baseline lumbar spine BMD was >1 g/cm2.115
Direct, region-specific measurements of bone formation and resorption in the femoral neck are hard to perform and have seldom been attempted. In a small study, there was no significant difference in regional bone formation between women with previous contralateral hip fracture and controls.119 While bone formation measured in the femoral neck correlated well with bone formation in the whole body measured radioisotopically,119 no correlation has been demonstrated yet between whole body and femoral neck bone resorption. Therefore, what follows needs to be interpreted with a degree of caution.
Markers of both whole-body bone resorption and formation may be elevated in elderly people, and correlate inversely with bone loss.120,121 In the numerically robust EPIDOS study, the odds ratio for risk of hip fracture in elderly women with a hip BMD of 2 SD or more below the premenopausal mean, was about 2 in those with elevated bone resorption markers, compared with an odds ratio of 2.7 for low hip BMD.122 Combinations of hip BMD and resorption markers increased the relative risk to 4.1–4.8. In a nested, case-control analysis within the Rotterdam study, an increase of 1 SD in total and free deoxypyridinoline concentrations was associated with a substantially higher risk of hip fracture.123
It was reported many years ago that patients with hip or vertebral fractures may have low vitamin K levels,124 and these findings have since been confirmed in controlled studies.125,126 In the EPIDOS study, femoral BMD was significantly lower in elderly women with under-carboxylated osteocalcin, which may be related to low vitamin K levels.127 High levels of under-carboxylated osteocalcin increased the relative risk of hip fracture to about 2, compared with 2.4 for low femoral neck BMD; again, combining these two risk factors raised the odds ratio to about 5.128 Levels of fully carboxylated osteocalcin can be restored to normal by vitamin K supplementation.77
Relationship of hip fractures to osteomalacia
The causes of vitamin D deficiency in the elderly include reduced sunlight exposure, low dietary intake and reduced intestinal absorption of vitamin D. In Western Europe, many studies have also implicated low 1,25-dihydroxy vitamin D levels, which may result from reduced renal synthesis.129 In North America, however, vitamin D deficiency in elderly people is less common, though the incidence of hip fracture is similar to that in the UK.130 The elderly population groups at high risk of osteomalacia in the UK are those who suffer malabsorption or malnutrition, the housebound or institutionalized, and those of Asian ethnicity.
Bone disease due to vitamin D deficiency falls into two types, which differ in their underlying pathophysiological processes. Severe vitamin D deficiency is associated with defective mineralization of bone, resulting in rickets in children and osteomalacia in adults.131 Subclinical vitamin D deficiency, which gives rise to increased bone turnover as a result of secondary hyperparathyroidism.132 The main histological differences between osteomalacia and secondary hyperparathyroidism are shown in Table 5. The cardinal difference is that mineralization is defective in osteomalacia, with a low or even absent mineral apposition rate. The disproportionately low rate of mineral apposition, compared with osteoid apposition, produces an increase in osteoid seam width, which is limited to osteomalacia and some very rare metabolic bone diseases. In secondary hyperparathyroidism, in contrast, actively forming surfaces and bone turnover are increased, with a normal or increased mineral apposition rate, and probably also an increased osteoid apposition rate. The seam width is usually normal, however, because mineralization keeps pace with osteoid formation.
|
Secondary hyperparathyroidism is very common in the elderly, and perhaps more so in hip fracture patients. Many of the discrepancies in the literature regarding the reported prevalence of osteomalacia in hip fracture patients are due to a failure to distinguish between these two different types of bone disease. Studies that have examined the prevalence of osteomalacia in hip fracture patients have produced results varying from 0% to 37%. Studies based on measurement of osteoid surface rather than seam width have found much higher prevalences133,134 than those studies using more rigorous histomorphometric criteria, which have generally reported prevalences of less than 2%.135–139
It thus appears that the prevalence of osteomalacia in hip fracture patients is similar to that seen in the elderly population in general, and that osteomalacia is not an important factor in the pathogenesis of hip fracture. Subclinical vitamin D deficiency, however, is likely to play an important role in the pathogenesis of hip fracture.
Bone turnover in forearm fracture
Although considerable information on BMD in relation to forearm fractures is available, the data on bone turnover in forearm fractures are scarce.
Following a forearm fracture, an increase in the biochemical markers of bone turnover has been reported.11,140–142 Markers of bone formation increase rapidly after forearm fracture, possibly related to callus formation, and remain elevated for at least 1 year.143 Markers of bone resorption also increase rapidly, and with the exception of deoxypyridinoline remain elevated for at least 1 year. Based on these findings and BMD data, normal bone turnover is probably not restored for about 2 years after a fracture. Immobilization may increase bone resorption and decrease bone formation.119,144
The rate of bone turnover may predict forearm bone loss,72 and rapid bone loss has been associated with fractures of the forearm and spine.73 In women with both Colles' and vertebral fractures, bone loss was similar at the spine and the ultradistal radius, and it was concluded that differential bone loss at the two sites may be a major factor in determining which will fracture.6 More studies are needed to confirm these findings and assess their significance.
Current understanding of bone dynamics is indicated in Table 6.
|
|
Management options for hip fracture |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Investigating patients with hip fracture
Low serum calcium levels are consistent with osteomalacia, and high serum calcium levels with primary hyperparathyroidism, which is present in 1% of postmenopausal women. A low serum calcium level, however, lacks specificity or sensitivity for the diagnosis of osteomalacia. If vitamin D deficiency or osteomalacia is suspected as a cause of hip fracture, vitamin D and calcium can be given without further tests. Epidemiological studies suggest that a past history of hyperthyroidism or thyroidectomy is a risk factor for hip fracture,46,145 and thyroid function tests may discover covert hyperthyroidism in the elderly without the classical signs or symptoms of thyrotoxicosis. Several studies have now shown that elderly men with hip fractures have a higher prevalence of low testosterone levels than control subjects,146,147 though this may be a secondary event relating to the fracture or surgery. Longitudinal studies are needed to clarify this issue. In elderly men, however, it may be undesirable to give testosterone replacement because of the risk of prostate cancer, so measurement of testosterone and gonadotrophins may be unnecessary in many cases.
Prevention of falls
The risk factors associated with falling may be intrinsic, e.g. poor vision, neurological disease or cardiovascular disease, and medication, and/or extrinsic or environmental, e.g. trailing wires, loose carpets or rugs, and inappropriate footwear. There has been considerable interest, particularly in elderly care circles, in trying to modify the environment in which the elderly faller lives.
In a randomized controlled trial in a residential care setting, intervention to modify both intrinsic and extrinsic factors over 2 years resulted in a significant decrease (26%) in hospital admissions, and non-significant decreases in falls (9%) and deaths (17%) compared with a control group who had no intervention.148 A larger randomized controlled study found that nutritional, medical, environmental and fitness intervention did not reduce fracture incidence over 4 years.149 Two controlled trials have shown that intervention to modify identified risk factors in individual patients can significantly reduce the incidence of falls,150,151 and in one of these studies the incidence of falls over 1 year was reduced by 60% and the incidence of fracture by 50%, though this last decrease was not statistically significant.150 Nutritional support has been shown to reduce the risk of subsequent hip fracture.152,153 From an elderly care point of view, however, encouragement to take a better diet and provision of nutritional support is difficult in the presence of cognitive impairment.
In a randomized trial in 1801 frail elderly patients (mean age, 82 years), use of external hip protectors reduced the risk of hip fracture by 60% over 2 years.154 The mean compliance rate with the hip protector was 48%, and most fractures in the hip protector group occurred when patients were not using the protector. In another study lasting 11 months, the risk of hip fracture was highly significantly reduced in subjects using the hip protectors; the only subjects using hip protectors who suffered a fracture did so when they were not wearing the hip protectors.155 In a more recent controlled cohort study, the relative risk for hip fracture in elderly nursing home residents (men and women) using hip protectors was 0.33 compared with residents not using hip protectors.156 Use of hip protectors may be the most promising approach, because the motivation to take tablets in elderly frail patients is often very low, and many are in residential care. However, the current randomized controlled trials of their benefit are of only low to moderate quality.157
Treatment options
There are currently no published studies on the secondary prevention of osteoporosis in the elderly presenting with hip fractures. The treatment options that can be extrapolated from other studies include HRT, bisphosphonates, and calcium plus vitamin D. The rationale for intervention with bone-active agents in elderly people presenting with hip fractures is derived from studies such as that of Jones et al., which showed that loss of BMD from the femoral neck continues into old age in both men and women.119
Oestrogen replacement can effectively prevent further bone loss in postmenopausal women with established osteoporosis. In a study of women with established osteoporosis, further loss of BMD was significantly reduced at the spine and reduced at the hip.158 The mean age of the women in the study (68 years), however, was much less than the mean age of women presenting with hip fractures, and HRT might thus only have a role in younger women presenting with hip fracture. It has recently been demonstrated, however, that low-dose HRT together with calcium and vitamin D can be safely given to women over 65 years of age, producing bone-sparing changes similar to those that occur with higher doses of HRT in younger postmenopausal women.159 In a case-control study of 1327 women aged 50–81 years with hip fracture and 3262 randomly selected controls, the risk of hip fracture was decreased in both current users of HRT (OR 0.35) and in former users (OR 0.76) compared with those who had never used it.160 HRT thus appears to be protective against hip fracture, but this benefit ceases within 5 years of stopping. Intracapsular fracture risk reverts more quickly to that of never-users than does extracapsular (trochanteric) hip fracture risk.161
Over a period of 3 years, cyclical etidronate produced an increase in femoral neck BMD of 1.4% compared with a decrease of 0.6% with placebo, which was a significant difference (p<0.05).162 Most studies with cyclical etidronate have only recruited women up to age 75 years, however, and so there are no data on efficacy in older women. In a recent study from the GP Research Database, about 30% of the patients were over the age of 75 years, and in these women the relative risk of hip fracture was significantly reduced by cyclical etidronate.163 Two studies with alendronate have recruited patients up to age 80 years, though neither of these included patients who already had a hip fracture.164,165 Nevertheless, the beneficial effect of alendronate on the incidence of hip fracture does not appear to decrease with age.166 Risedronate reduces the risk of hip fracture in patients with low BMD, but not in women at increased risk of falling. In a study of 9331 women, those who were under the age of 80 years and had a T score below -3, had a relative risk of hip fracture of 0.7 with risedronate therapy.167 Women over 80-years-old were selected primarily on the basis of non-skeletal risk factors, and in this group there was no change in the risk of hip fracture with risedronate treatment.
In the very frail or elderly, the most attractive option is vitamin D with calcium. In a study of very elderly (mean age 84 years), healthy and ambulatory women living in nursing homes or apartment houses for the elderly, calcium plus vitamin D significantly reduced the risk of hip and other non-vertebral fractures.106 Annual injections of vitamin D, 150 000 IU or 300 000 IU, reduced the risk of fracture by about 25% over 5 years in elderly patients either attending an elderly care out-patient clinic or living in a municipal home for the elderly, though the changes were not significant at any single site.168 Other data indicate that calcium plus vitamin D also has a beneficial effect on BMD in younger men and women and reduces the risk of non-vertebral fractures.169
In contrast, although Lips et al. were able to show a small but significant beneficial effect (2.2% after 2 years) of low-dose vitamin D on hip BMD, there was no effect on fracture rate at the hip or other appendicular sites.170 It thus appears that vitamin D and calcium may be beneficial, but there are no data in secondary prevention of hip fracture. A double-blind randomized controlled trial is currently in progress to enrol 6000 men and women over 70-years-old with osteoporosis-related fractures and investigate the effects of vitamin D or calcium over 3.5 years on various outcome measures, including fractures, BMD, and falls. Recruitment started in early 1999.
|
Management options for Colles' fracture |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Despite the clear indication that Colles' fracture is an osteoporotic fracture, in the vast majority of cases no measures are initiated to protect patients from subsequent, more serious fractures. The general approaches that could be considered are identification of those at increased risk and provision of appropriate treatment, either before or after the occurrence of a Colles' fracture, depending on whether or not the patient has a coexisting vertebral fracture.
Investigating patients with Colles' fracture
Although several factors increase the risk of Colles' fracture, these do not identify individuals at risk, and any treatment offered on this basis would have to be generally appropriate. Investigations following a first Colles' fracture can document the presence of osteoporosis, predict the risk of future fracture, and estimate the risk of future falling. About 21–42% of Colles' fracture patients fulfil the WHO criteria for osteoporosis, depending on the site of measurement,11 representing 35% of those under 66 years of age and 64% of those over 66 years of age.
Treatment options
The options available at present are general measures (diet adequate in calcium and vitamin D, regular exercise, avoidance of smoking and excess alcohol consumption), hormone replacement therapy (HRT), calcitonin plus calcium, or a bisphosphonate, but very few studies have been published. In a prospective study of 245 women commencing HRT for reasons not related to osteoporosis, the risk of Colles' and vertebral fracture was reduced overall compared with a matched control group not using HRT, but with a trend to diminishing protection with increasing age.171
In the Fracture Intervention Trial (FIT), 2027 postmenopausal women with a hip BMD T score of -2 SD or below and at least one prevalent vertebral fracture were randomized to receive either placebo or alendronate, 5 mg/day for 2 years, then 10 mg/day for 1 year.165 Both the alendronate-treated and the placebo groups received calcium and a supplemented intake of vitamin D where appropriate. About 4% of those who received placebo sustained a Colles' fracture during the 3-year study, compared with 2% of those receiving alendronate (p=0.013), corresponding to a relative risk of 0.52. In women with the same BMD criteria but without a vertebral fracture, only about 4% sustained a Colles' fracture during the 4.5 years of follow-up; this proportion was not significantly altered by the use of alendronate, 5 mg/day for 2 years, then 10 mg/day for at least 2 years, and there was little effect on forearm BMD.172 It thus appeared that in this latter study population, alendronate did not decrease the risk of a new Colles' fracture.
In a study of 45 postmenopausal women with Colles' fracture, treatment with salmon calcitonin, 100 IU/day, plus calcium, 1200 mg/day, for 10 days each month for 12 months significantly increased metacarpal index by 12.8%.173 Treatment with calcium alone also significantly increased metacarpal index, but to a lesser degree, whereas metacarpal index decreased in those receiving placebo. This study was too small to have a fracture end-point.
The management options for hip and Colles' fracture are summarized in Table 7.
|
|
Implementation in secondary care |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Based on the epidemiological data presented in this review, and on the established relationship between BMD and prevalent and future fractures, the Consensus Group believes that any patient who has suffered a Colles', hip, proximal humerus, pelvis, and/or rib fracture should undergo further investigation and/or treatment. Clinical experience suggests that this represents more than 250 patients/year in each General Hospital, who present at fracture or orthopaedic clinics or wards with these fractures, and would be considered at increased risk of subsequent osteoporosis-related fractures. The most cost-effective approach to this increased workload would be the use of specialists nurses, who could ensure appropriate follow-up of patients between orthopaedic and osteoporosis specialist departments, manage the appropriate diagnostic tests under the supervision of the interested physician, interpret test results and offer management advice to GPs via standard letters.
After considering the available data, the Consensus Group believes that the clinical approach to management of individual patients at risk should be differentiated according to the type of fracture sustained. The guidance offered below was therefore formulated for distal forearm fracture patients alone, and separately for patients with moderate-to-low trauma fractures of the hip, rib, proximal humerus and pelvis. The management algorithm shown in Figure 5, which is discussed in detail below, is based on that recently published by the Royal College of Physicians174 and represents the current judgement of the Consensus Group. The Group recognizes, however, that in view of the absence of data in some areas, not all of the measures are evidence-based. As far as possible, therapeutic recommendations are based on the published literature to date. The guidance has been formulated with practicality in mind.
|
Major risk factors include untreated hypogonadism, high-dose glucocorticoid treatment, disease associated with increased prevalence of osteoporosis (e.g. gastrointestinal disease, chronic liver disease, hyperparathyroidism, hyperthyroidism). Other risk factors include tendency to falling, family history, low body weight, cigarette smoking, height loss, low bone mass measured by other techniques. 
If not done within the previous 6 months: full blood count and erythrocyte sedimentation rate; serum calcium, phosphate and alkaline phosphatase; protein electrophoresis and urine screen for light chains; thyroid function tests; total testosterone or free androgen index (men); vitamin D and parathyroid hormone levels (if serum calcium and alkaline phosphatase are abnormal). 
T score is the BMD result expressed in SD units where the mean value for a young person is 0. ¶Listed in alphabetical order. Vitamin D and calcium are generally regarded as adjuncts to treatment. HRT means oestrogen in women and testosterone in hypogonadal men. From the Royal College of Physicians and the Bone and Tooth Society.Moderate-to-low trauma fractures of the hip, rib, proximal humerus, or pelvis
The management of patients with hip fracture involves a combined orthopaedic and elderly care approach, because both surgical fixation of the fracture and subsequent rehabilitation are necessary in order to allow optimal recovery of functional capacity. Ideally, the risk of future fractures as a result of further falls should be reduced by minimizing further bone loss and falls, and by limiting the damage caused by any falls that do occur.
Clinical assessment
If secondary osteoporosis is suspected, the following diagnostic tests are recommended, if they have not been done within the previous 6 months, to exclude myeloma, hyperparathyroidism, osteomalacia, malabsorption, thyrotoxicosis and hypogonadism: full blood count and erythrocyte sedimentation rate; serum calcium, phosphate and alkaline phosphatase; protein electrophoresis and urine screen for light chains; thyroid function tests; total testosterone or free androgen index (men); vitamin D and parathyroid hormone levels (if serum calcium and alkaline phosphatase are abnormal). Any abnormalities detected in the work-up should be followed-up appropriately. Although men over 75 years old may benefit from testosterone treatment, the possibility that microscopic prostate cancer may be stimulated must be considered.
Therapeutic intervention
All patients with hip or low-trauma fractures of the rib, proximal humerus, or pelvis should be offered general advice on lifestyle measures to decrease bone loss, including eating a balanced diet rich in calcium, not smoking or drinking alcohol to excess, and maintaining regular exercise and adequate exposure to sunlight.
After consideration of lifestyle and home environment factors, patients with hip or other low-trauma fractures can be divided into two main groups. The first group comprises those who are frail, elderly and/or in residential care, and who have a limited life expectancy or seldom venture outdoors. In these patients, who are often vitamin-D-deficient, it is probably inappropriate to perform substantial investigations to exclude secondary causes of osteoporosis or to confirm the diagnosis by bone densitometry. These patients are more likely to benefit from calcium plus vitamin D supplementation than from other therapeutic recommendations.106 The use of hip protectors to reduce the impact of any falls may also be considered. If a second fracture occurs, calcium plus vitamin D should be continued and a bisphosphonate added.
The second group comprises patients who are independent and were mobile before the fracture occurred. Those who are over 75 years of age may be treated with calcium plus vitamin D supplementation without further investigation. Those patients in this group who are under 75 years of age will benefit from more active investigation and intervention, as their life expectancy and quality of life can be improved by decreasing the risk of further fractures (Figure 5 and Table 8).
|
BMD has been considered to be of limited value in the diagnosis of osteoporosis in elderly patients with hip fracture, as most will have a reduced BMD and the results are unlikely to influence management. The recent results of the risedronate hip fracture studies,167 in which patients over 80 years old who were not documented to have reduced BMD benefited less than slightly younger patients who were known to have low BMD, will probably occasion a re-investigation of the value of BMD measurement in the over-80s. In younger independent patients, dual-energy X-ray absorptiometry (DXA) is useful to identify those with a low BMD. In the elderly the optimal measurement site is the proximal femur, as lumbar spine BMD may be artifactually elevated in the elderly due to degenerative changes.175 When DXA is not available, measurements such as single-energy X-ray absorptiometry of the forearm and possibly ultrasound measurements of the heel may be considered as alternative methods for risk assessment, though there are limited data on their usefulness in a more elderly population. Moreover, BMD guidelines based on DXA may not be applicable to these other techniques.
Although no secondary prevention studies of the treatment of osteoporosis in elderly patients have yet been published, treatment with bisphosphonates and/or calcium plus vitamin D is recommended for independent patients under 75 years of age with low bone mass. Other treatments to consider are raloxifene, calcitriol, or HRT.
Follow-up
For those patients who have started therapy following diagnostic investigations, the response to therapy may be assessed with measurements of hip BMD after 2 years and then every 2–3 years as appropriate. If bone loss at the hip is >7%, an alternative therapy should be considered. This figure is based on, and is in excess of, the least significant change detectable at the hip. In the future, biochemical markers may be available as an alternative monitoring method.
Distal forearm fracture
Colles' fracture alone is not sufficiently predictive of risk to warrant therapeutic intervention. A more detailed assessment of risk is required in women aged <75 years with forearm fracture (Figure 5). Recently, the risk factors specific to Colles' fracture have been identified as a history of wrist fracture, low body weight, a low calcium intake, and non-use of HRT.176 In the presence of all four risk factors, risk was increased 12-fold (increasing to 30-fold in women who were postmenopausal), but the sensitivity and specificity of the risk factor score remained low because of the small number of women with more than one risk factor.
Management approaches
It has been proposed by a working group of the National Osteoporosis Foundation that a hip BMD T score of -3 to -1.5 SD should be used to make decisions about treatment, taking into account other risk factors.177 T score is the BMD result expressed in SD units, where the mean value for a young person is 0. A T score for hip BMD of -2.5 SD is found in 22% of women over 50 years old and in 40% of those over 80 years old. Between one-quarter and one-third of women over 65 years old have a T score of -2.5 SD, and 64% of women over the age of 66 years with forearm fractures have a T score below –2.5 SD when measured at the hip, spine, or ultradistal radius.11 Measurement of BMD is therefore of value if it is proposed to use a bisphosphonate, when appendicular anti-fracture efficacy may only be apparent in those with low BMD.167,172
In patients aged 65–75 years with a low-impact Colles' fracture, or in those under 65 years of age who are unwilling to take HRT, osteoporosis should be considered and BMD measured by DXA where possible (Figure 5). As discussed previously, DXA should be limited to the proximal femur in the more elderly group,11 or measured at the lumbar spine and proximal femur in younger patients.
In patients with a Colles' fracture and T score for BMD below -2.5 SD, a cause for secondary bone loss should be excluded by appropriate diagnostic investigations (as outlined above for patients with moderate-to-low trauma fractures). Any abnormalities found during investigation should be treated as appropriate for the underlying condition.
Patients with a Colles' fracture and a T score for BMD of -1 to -2.5 SD do not usually require further diagnostic tests. Their BMD should be assessed again after 5 years. Patients with BMD T scores greater than 0 SD should be reassured that they are at low risk of osteoporosis.
As with hip fracture, when DXA is not available, measurements such as single-energy X-ray absorptiometry of the forearm and possibly ultrasound measurements of the heel may be considered as alternative methods for risk assessment.
Therapeutic interventions
In most cases the GP can initiate treatment on the basis of the recommendations from the hospital. In some centres, a nurse specialist takes on the role of discussing treatment options with the patient, under the supervision of an interested clinician involved in osteoporosis. In this case, for the first year the clinician would review the decision process and countersign all the forms, but after that the nurse specialist would assume responsibility for informing the GP. It is essential that whoever makes the recommendations on long-term treatment understands the case thoroughly and presents all the necessary information to the GP.
All patients should be offered lifestyle advice (see Moderate-to-low trauma fractures, Therapeutic intervention). In patients over 75 years of age, calcium plus vitamin D supplementation or a bisphosphonate are the most appropriate active therapies, without the need for further investigation.
Patients aged 65–75 years, or women aged <65 years but unwilling to take HRT, and with a low bone mass (T score of -2.5 SD or below), in whom secondary causes have been excluded or treated, should be treated with a bisphosphonate, HRT, or raloxifene to increase bone mass. Calcium plus vitamin D supplementation (or calcitriol) is another option. HRT, alendronate and risedronate have all been shown to reduce the risk of non-vertebral fracture. Most studies using HRT are not randomized controlled trials and must be interpreted with caution. There is no evidence that raloxifene prevents fractures other than vertebral fractures.
Follow-up
The response to therapy of patients with Colles' fractures may be monitored using DXA every 2 years. If bone loss at the hip is significant, then an alternative therapy should be considered.
|
Cost-benefit analysis of treatment of Colles', hip and other fractures |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
The Advisory Group of Osteoporosis estimated in 1994 that the annual costs of osteoporosis in the UK were £742m (1992/1993 prices).178 A more recent cost assessment exercise included fracture costs for men as well as women, increasing the total estimate to £1.7 billion/year, of which over 20% was associated with the costs of treating hip fracture in men.4
The costs of hip fracture comprise several components, including in-patient costs, post-fracture out-patient and GP care, and institutional care, and may reach £20 000.4 In a prospective assessment, the costs of hip fracture (Australian $15 984) were substantially greater than those for in-patient treatment of distal radial fractures (Australian $4075), upper or lower limb fractures (Australian $3057 and Australian $6211, respectively), and other fractures (Australian $9116).179 Fractures treated on an in-patient basis were more costly than those treated on an out-patient basis, as were fractures in hospitalized patients aged 
75 years compared with those aged <75 years. In 1997, the US National Osteoporosis Foundation estimated the total costs for first year events in hip fracture patients to be US $28 242 for those aged 50–54 years, US $26 227 for those aged over 65 years, with nursing home costs of US $27 516.177 The lower costs in the older patients may reflect their earlier discharge to nursing homes. In the same analysis, the costs of acute treatment of both wrist fracture and vertebral fractures were US $1000. In the recent UK estimate, the total costs of hip fracture (£12 000) were also substantially greater than for wrist, vertebral and other fractures (£468, £479, and £1338, respectively).3
Drug costs after fracture
The cost of the various therapeutic agents available for use after fracture vary from just over £7/30 days to just over £70/30 days.180 The National Osteoporosis Foundation analysis of the cost-effectiveness of treatment assumed that bisphosphonates typically produced a 50% overall reduction in the risk of further fracture for an annual cost of $740, that calcium and vitamin D produced a 10% reduction in all-site fracture risk for an annual cost of $50, and that calcitonin did not reduce the risk of hip or wrist fracture but reduced the risk of vertebral fracture by 75% for an annual cost of $740.177 The base analysis assumed 100% compliance with 5 years of treatment.
The discounted costs per vertebral fracture avoided by use of HRT, cyclical etidronate and salmon calcitonin were estimated at between £138 and £25013 in 1995, with salmon calcitonin considerably the most expensive; the treatments were all considered to reduce the incidence of further fracture by 50–60%, so the costs reflect the medication costs.181 This indicates that although salmon calcitonin appears to be as effective as the other treatments, it should be reserved for situations in which HRT or bisphosphonates are inappropriate.
Costs of gaining quality-adjusted life years
The National Osteoporosis Foundation sets the value of a quality-adjusted life year (QALY) at US $30 000.177 This sum is simply the per capita Gross National Product of the USA in 1998; an equivalent figure in several large Western European countries would be $20 000–22 000. The number of QALYs lost following fracture depends on the type of fracture (Table 9).177 In a recent overview, the cost per QALY gained by HRT varied from about US $12 000 to about US $50 000 for symptomatic women, but was considerably more for asymptomatic women (US $28 000–US $73 000).182 The flaws of cost-utility analyses of HRT are that these studies assumed that HRT was required for only 5–10 years and that compliance was good. It is known that long-term compliance with HRT may be poor.28,107,108 The small increase in risk of breast cancer with long-term use of HRT183 would reduce the likely health gain, though the expected decrease in ischaemic heart disease would increase the likely health gain.184
|
Based on their estimate of the monetary value of a QALY (US $30 000), the National Osteoporosis Foundation suggested that in relation to bisphosphonate treatment, BMD measurement is cost-effective for women without a previous fracture who are either >65 years old or who are >60 years old with one or more additional risk factors.177 For women with a previous non-vertebral or vertebral fracture, BMD screening is cost-effective in those >60 years old and in those >50 years old with one or more additional risk factors. The US estimate of an acceptable cost/QALY is higher than would be acceptable by publicly funded healthcare systems in most other countries.
A descriptive cost-benefit analysis of treatment for non-vertebral fractures is presented in Table 10.
|
|
Conclusion |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
Non-vertebral fractures are common, affecting 1% of the population/year. One fracture commonly predicts a second fracture, e.g. the risk of vertebral fracture increases fivefold in patients with distal forearm fracture. Fracture patients are therefore a suitable target for treatments to prevent further fractures. This Consensus Group proposes a treatment algorithm used based on that described by the joint report of the Royal College of Physicians and the Bone and Tooth Society. Preventive measures should be taken in patients who sustain non-vertebral fracture and whose bone density indicates osteopenia or osteoporosis.
|
Acknowledgments |
|---|
The material in this publication represents the views and opinions of the named authors. This manuscript is based on a meeting held with the help of a scientific grant from the Alliance for Better Bone Health. For detailed efficacy and safety and licensed status information on any of the drugs discussed herein, please consult the relevant prescribing information.
|
Notes |
|---|
Address correspondence to Professor R. Eastell, University of Sheffield Medical School, Northen General Hospital, Herries Road, Sheffield S5 7AU. e-mail: r.eastell{at}sheffield.ac.uk
|
References |
|---|
|
TopSummaryIntroductionEpidemiology of fractureRisk factors for fractureBone turnover and calcium...Management options for hip...Management options for Colles'...Implementation in secondary careCost-benefit analysis of...ConclusionReferences |
|---|
1. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health1990; 44:241–5.
2. Sheehan J, Mohamed F, Reilly M, Perry IJ. Secondary prevention following fractured neck of femur: a survey of orthopaedic surgeons practice. Irish Med J2000; 93:105–7.
3. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int1998; 8:611–17.[Web of Science][Medline]
4. Torgerson DJ, Iglesias CP, Reid DM. The economics of fracture prevention. In: Barlow DH, ed. The Effective Management of Osteoporosis. London, Aesculapius Medical Press, 2001:111–21.
5. Garraway WM, Stauffer RN, Kurland LT, O’Fallon WM. Limb fractures in a defined population. II. Orthopedic treatment and utilization of health care. Mayo Clin Proc1979; 54:708–13.[Web of Science][Medline]
6. Eastell R, Wahner HW, O'Fallon M, Amdio PC, Melton LJ III, Riggs BL. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest1989; 83:168–74.
7. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM, the Study of Osteoporotic Fractures Research Group. Bone density at various sites for prediction of hip fractures. Lancet1993; 341:72–5.[Web of Science][Medline]
8. Bauer DC, Glüer CC, Genant HK, Stone K, the Fracture Intervention Trial Research Group. Quantitative ultrasound and vertebral fracture in postmenopausal women. J Bone Miner Res1995; 10:353–8.[Web of Science][Medline]
9.
Bauer DC, Glüer CC, Cauley JA, Vogt TM, Ensrud K, Genant HK, Black DM, the Study of Osteoporotic Fractures Research Group. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. Arch Intern Med1997; 157:629–34.
10. Dai LY, Chen DY, Wu DS, Wen Y. Osteoporosis in Colles' fracture. Arch Orthop Trauma Surg1998; 117:65–7.
11. Earnshaw SA, Cawte SA, Worley A, Hosking DJ. Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate. Osteoporos Int1998; 8:53–60.[Web of Science][Medline]
12. Johansen A, Evans RJ, Stone MD, Richmond PW, Lo SV, Woodhouse KW. Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury1997; 28:655–60.[Web of Science][Medline]
13.
Adebajo AO, Cooper C, Grimley Evans J. Fractures of the hip and distal forearm in West Africa and the United Kingdom. Age Ageing1991; 20:435–8.
14. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol1993; 7:459–77.[Web of Science][Medline]
15. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a worldwide projection. Osteoporos Int1992; 2:285–9.[Web of Science][Medline]
16. Dennison E, Cooper C. The epidemiology of osteoporosis. Br J Clin Pract1996; 50:33–6.[Web of Science][Medline]
17. Johnell O, Gullberg B, Allander E, Kanis JA, MEDOS Study Group. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int1992; 2:298–302.[Web of Science][Medline]
18. Aspray TJ, Prentice A, Cole T, Sawo Y, Reeve J, Francis RM. Low bone mineral content is common but osteoporotic fractures are rare in elderly rural Gambian women. J Bone Miner Res1996; 11:1019–25.[Web of Science][Medline]
19. Cooper C, Melton LJ III. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, Academic Press, 1996:419–34.
20. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res1992; 7:1005–10.[Web of Science][Medline]
21. Bengnér U, Johnell O. Increasing incidence of forearm fractures: a comparison of epidemiological pattern 25 years apart. Acta Orthop Scand1985; 56:158–60.[Web of Science][Medline]
22.
Owen RA, Melton LJ III, Johnson KA, Ilstrup DM, Riggs BL. Incidence of Colles' fracture in a North American community. Am J Public Health1982; 72:605–7.
23. Arden N, Cooper C. Present and future of osteoporosis: epidemiology. In: Meunier PJ, ed. Osteoporosis: Diagnosis and Management. London, Martin Dunitz, 1998:1–16.
24. Melton LJ III. Epidemiology of fractures. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York, Raven Press, 1988:133–54.
25. Baron JA, Barrett JA, Karagas MR. The epidemiology of peripheral fractures. Bone1996; 18(Suppl. 3):209–13S.
26. Baron JA, Barrett JA, Malenka D, Fisher E, Kniffin W, Bubolz T, Tosteson T. Racial differences in fracture risk. Epidemiology1994; 5:42–7.[Web of Science][Medline]
27. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int1994; 4:277–82.[Web of Science][Medline]
28. Obrant KJ, Bengnér U, Johnell O, Nilsson BE, Sernbo I. Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int1989; 44:157–67.[Web of Science][Medline]
29.
Kannus P, Palvanen M, Niemi S, Parkkari J, Järvinen M, Vuori I. Increasing number and incidence of osteoporotic fractures of the proximal humerus in elderly people. Br Med J1993; 313:1051–2.
30. Spector TD, Cooper C, Lewis AF. Trends in admissions for hip fracture in England and Wales, 1968–85. Br Med J1990; 300:1178–84.
31. Melton LJ III, Atkinson EJ, Madhok R. Down turn in hip fracture incidence. Public Health Rep1996; 3:146–50.
32. Washington DC Office of Technology Assessment Congress of the United States. Expenditures and long-term functional impairment. Washington DC, US Department of Commerce, 1993.
33. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med1997; 103(Suppl. 2a):12–19S.[Web of Science]
34. Poór G, Jacobsen SJ, Melton LJ III. Mortality after hip fracture. Facts Res Gerontol1994; 7:91–109.
35. Poór G, Atkinson EJ, O’Fallon WM, Melton LJ III. Determinants of reduced survival following hip fractures in men. Clin Orthop1995; 319:260–5.
36. Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated with mortality after hip fracture. Osteoporos Int2000; 11:228–32.[Web of Science][Medline]
37. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res1993; 8:1227–33.[Web of Science][Medline]
38. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis. Br Med J1989; 298:924–8.
39.
Earnshaw SA, Hosking DJ. Clinical usefulness of risk factors for osteoporosis. Ann Rheum Dis1996; 55:338–9.
40. Elders PJ, Netelenbos JC, Lips P, Khoe E, van Ginkel FC, Hulshof KF, van der Stelt PF. Perimenopausal bone mass and risk factors. Bone Miner1989; 7:298–9.
41. Kleerekoper M, Peterson E, Nelson D, Tilley B, Phillips E, Schork MA, Kuder J. Identification of women at risk of developing postmenopausal osteoporosis with vertebral fractures: role of history and single photon absorptiometry. Bone Miner1989; 7:171–86.[Web of Science][Medline]
42. Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC. Predictors of bone mass in perimenopausal women: a prospective study of clinical data using photon absorptiometry. Ann Intern Med1990; 112:96–101.
43. Ribot C, Pouilles JM, Bonneu M, Tremollières F. Assessment of the risk of post-menopausal osteoporosis using clinical factors. Clin Endocrinol (Oxf)1992; 36:225–8.[Medline]
44. Kroger H, Tuppurainen M, Honkanen R, Alhava E, Saarikoski S. Bone mineral density and risk factors for osteoporosis: a population-based study of 1600 perimenopausal women. Calcif Tissue Int1994; 55:1–7.[Web of Science][Medline]
45. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of gynaecological risk factors on lumbar and femoral bone mineral density in peri- and postmenopausal women. Maturitas1995; 21:137–45.[Web of Science][Medline]
46.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM, the Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N Engl J Med1995; 332:767–73.
47. Seeman E, Tsalamandris C, Formica C, Hopper JL, McKay J. Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res1994; 9:739–43.[Web of Science][Medline]
48.
Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C. Programming of growth hormone secretion and bone mineral density in elderly men: an hypothesis. J Clin Endocrinol Metab1998; 83:135–9.
49.
Dennison E, Hindmarsh P, Fall C, Kellingray S, Barker D, Phillips D, Cooper C. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab1999; 84:3058–63.
50.
Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, Hofman A, van Leeuwen JP, Pols HA, Ralston SH. Relation of alleles of the collagen type I alpha 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med1998; 338:1061–2.
51.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J1996; 312:1254–9.
52. Kroger H, Lunt M, Reeve J, Dequeker J, Adams J, Birkenhager J, Diaz-Curiel M, Felsenberg D, Hyldstrup L, Kotzki P, Laval-Jeantet A, Lips P, Louis O, Perez-Cano R, Reiners C, Ribot C, Ruegsegger P, Schneider P, Braillon P, Pearson J. Bone density reduction in various measurement sites in men and women with osteoporotic fractures of spine and hip: the European quantitation of osteoporosis study. Calcif Tissue Int1999; 64:191–9.[Web of Science][Medline]
53. Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, Kotzki PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet1996; 348:511–14.[Web of Science][Medline]
54. Pluijm SMF, Graafmans WC, Bouter LM, Lips P. Ultrasound measurements for the prediction of osteoporotic fractures in elderly people. Osteoporosis Int1999; 9:550–6.[Web of Science][Medline]
55. Stewart A, Walker LG, Porter RW, Reid DM, Primrose WR. Predicting a second hip fracture. The potential role of dual X-ray absorptiometry, ultrasound and other risk factors in targeting of preventive therapy. J Clin Densitom1999; 2:363–70.[Web of Science][Medline]
56. Nilsson BE, Westlin NE. The bone mineral content in the forearm of women with Colles' fracture. Acta Orthop Scand1974; 45:836–44.[Web of Science][Medline]
57. Jensen UF, Christiansen C, Boesen J, Hegedus V, Transbol I. Relationship between one mineral content and frequency of postmenopausal fractures. Acta Med Scand1983; 213:61–3.[Web of Science][Medline]
58. Hesp R, Klenerman L, Page L. Decreased radial bone mass in Colles' fracture. Acta Orthop Scand1984; 55:573–5.[Web of Science][Medline]
59. Harma M, Karjalainen P. Trabecular osteopenia in Colles' fracture. Acta Orthop Scand1986; 57:38–40.[Web of Science][Medline]
60.
Crilly RG, Delaquerriere-Richardson L, Roth JH, Vandervoort AA, Hayes KC, Mackenzie RA. Postural stability and Colles' fracture. Age Ageing1987; 16:133–8.
61. Eastell R, Riggs BL, Wahner HW, O'Fallon M, Amadio PC, Melton LJ III. Colles' fracture and bone density of the ultradistal radius. J Bone Miner Res1989; 4:607–13.[Web of Science][Medline]
62.
Smith DAS, Hosie CJ, Deacon ND, Hamblen DL. Quantitative x-ray computed tomography of the radius in normal subjects and osteoporotic patients. Br J Radiol1990; 63:776–82.
63. Ooms ME, Lips P, Van Lingen A, Valkenburg HA. Determinants of bone mineral density and risk factors for osteoporosis in healthy elderly women. J Bone Miner Res1993; 8:669–75.[Web of Science][Medline]
64. Mallmin H, Ljunghall S. Distal radius fracture is an early sign of general osteoporosis: bone mass measurements in a population-based study. Osteoporos Int1994; 4:357–61.[Web of Science][Medline]
65. Krolner B, Tondevold E, Toft B, Berthelsen B, Nielsen SP. Bone mass of the axial and the appendicular skeleton in women with Colles' fracture: its relation to physical activity. Clin Physiol1982; 2:147–57.[Web of Science][Medline]
66. Nordin BEC, Crilly RG, Smith DA. Osteoporosis. In: Nordin BEC, ed. Metabolic Bone and Stone Disease. New York, Churchill Livingstone, 1984:1–70.
67.
Kelsey JL, Browner WS, Seeley DG, Nevitt MC, Cummings SR, the Study of Osteoporotic Fractures Research Group. Risk factors for fractures of the distal forearm and proximal humerus. Am J Epidemiol1992; 135:477–89.
68. Fatayerji D, Cooper AM, Eastell R. Total body and regional bone mineral density in men: effect of age. Osteoporos Int1999; 10:59–65.[Web of Science][Medline]
69. Harma M, Karjalainen P. Trabecular osteopenia in Colles' fracture. Acta Orthop Scand1986; 57:38–40.
70.
Peel NF, Barrington NA, Smith TW, Eastell R. Distal forearm fracture as risk factor for vertebral osteoporosis. Br Med J1994; 308:1543–4.
71. Kroger H, Jurvelin J, Arnala I, Penttila K, Rask A, Vainio P, Alhava E. Ultrasound attenuation of the calcaneus in normal subjects and in patients with wrist fractures. Acta Orthop Scand1995; 66:47–52.[Web of Science][Medline]
72. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. Br Med J1991; 303:961–4.
73. Riis BJ, Hansen MA, Jensen AM, Overgaard K. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone1996; 19:9–12.[Medline]
74.
Peel NF, Smith AG, Hannon RA, Eastell R. Rate of bone loss from lumbar spine in women with distal forearm fracture. Br Med J1996; 312:1457.
75.
Keen RW, Griffiths GO, Spector TD. Patients who have had fractures of the distal forearm do not lose bone as expected [letter]. Br Med J1996; 313:821.
76. Cuddihy M-T, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ III. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int1999; 9:469–75.[Web of Science][Medline]
77. Douglas AS, Robins SP, Hutchison JD, Porter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in postmenopausal osteoporotic women following vitamin K and D supplementation. Bone1995; 17:15–20.[Medline]
78. Owen RA, Melton LJ III, Ilstrup DM, Johnson KA, Riggs BL. Colles' fracture and subsequent hip fracture risk. Clin Orthop Rel Res1982; 171:37–43.
79.
Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med1994; 87:203–9.
80. Eastell R. Forearm fracture. Bone1996; 18(Suppl):203–7S.
81. Davie MWJ. Fractures at specific sites indicate low bone mineral density at lumbar spine and femoral neck in women. J Orthop Rheumatol1996; 9:41–5.
82. Honkanen R, Kröger H, Tuppurainen M, Alhava E, Saarikoski S. Fractures and low axial bone density in perimenopausal women. J Clin Epidemiol1995; 48:881–8.[Web of Science][Medline]
83. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR, the Study of Osteoporotic Fractures Research Group. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med 1991; 115:837–42.
84. Seeley DG, Kelsey J, Jergas M, Nevitt MC, the Study of Osteoporotic Fractures Research Group. Predictors of ankle and foot fractures in older women. J Bone Miner Res1996; 11:1347–55.[Web of Science][Medline]
85. Eastell R, Mosekilde L, Hodgson SF, Riggs BL. Proportion of human vertebral body that is cancellous. J Bone Miner Res1990; 5:1237–41.[Web of Science][Medline]
86. Köwitz J, Knippel M, Schuhr T, Mach J. Alteration in the extent of collagen I hydroxylation, isolated from femoral heads of women with a femoral neck fracture caused by osteoporosis. Calcif Tissue Int1997; 60:501–5.[Web of Science][Medline]
87. Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res1997; 12:641–51.[Web of Science][Medline]
88. Dunstan CR, Evans RA, Hills E, Wong SY, Higgs RJ. Bone death in hip fracture in the elderly. Calcif Tissue Int1990; 47:270–5.[Web of Science][Medline]
89. Power J, Noble BS, Loveridge N, Bell KL, Rushton N, Reeve J. Osteocyte viability in the femoral neck cortex: an association with cortical remodelling in cases of hip fracture and controls. Calcif Tissue Int2001; in press.
90. Recker RR. Architecture and vertebral fracture. Calcif Tissue Int1993; 53(Suppl. 1):S139–42.
91. Schnitzler CM, Pettifor JM, Mesquita JM, Bird MD, Schnaid E, Smyth AE. Histomorphometry of iliac crest bone in 346 normal black and white South African adults. Bone Miner1990; 10:183–99.[Web of Science][Medline]
92. Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM. Effects of ethnicity and age or menopause on the remodelling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res1997; 12:498–508.[Web of Science][Medline]
93. Nelson DA, Barondess DA, Hendrix SL, Beck TJ. Cross-sectional geometry, bone strength and bone mass in the proximal femur in black and white postmenopausal women. J Bone Miner Res2000; 15:1992–7.[Web of Science][Medline]
94. Cummings SR, Cauley JA, Palermo L, Ross PD, Wasnich RD, Black D, Faulkner KG, the Study of Osteoporotic Fractures Research Group. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Osteoporos Int1994; 4:226–9.[Web of Science][Medline]
95. Boonen S, Koutri R, Dequecker J, Aerssens J, Lowet G, Nijs J, Verbeke G, Lesaffre E, Geusens P. Measurement of femoral geometry in type I and type II osteoporosis: differences in hip axis length consistent with heterogeneity in the pathogenesis of osteoporotic fractures. J Bone Miner Res1995; 10:1908–12.[Web of Science][Medline]
96. Crabtree NJ, Kroger H, Martin A, Pols HAP, Lorenc R, Nijs J, Stepan JJ, Falch JA, Miazgowski T, Grazio S, Raptou P, Adams J, Collings A, Khaw KT, Rushton N, Lunt M, Dixon AK, Reeve J. Improving risk assessment: hip geometry, bone mineral distribution and bone strengthin hip fracture cases and controls. The EPOS study. Osteoporos Int2001; in press.
97. Crabtree NJ, Lunt M, Holt G, Kroger H, Burger H, Grazio S, Lorenc R, Nijs J, Stepan JJ, Falch JA, Miazgowski T, Raptou P, Pols HAP, Dequeker J, Havelka S, Hoszowski K, Jajic I, Czekalski S, Lyritis G, Silman AJ, Reeve J. Hip geometry, bone mineral distribution and bone strength in European men and women: the EPOS study. Bone2000; 27:151–60.[Medline]
98. Beck TJ, Looker AC, Ruff CB, Sievanen H, Wahner HW. Structural trends in the ageing femoral neck and proximal shaft: analysis of the third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res2000; 15:2297–308.[Web of Science][Medline]
99. O’Neill TW, Grazio S, Spector TD, Silman AJ. Geometric measurements of the proximal femur in U K women: secular increase between the late 1950s and early 1990s. Osteoporos Int1996; 6:136–40.[Web of Science][Medline]
100.
Reid IR, Chin K, Evans MC, Jones JG. Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age-specific rates of hip fracture. Br Med J1994; 309:508–9.
101. Winner SJ, Morgan CA, Grimley Evans J. Perimenopausal risk of falling and incidence of distal forearm fracture. Br Med J1989; 298:1486–8.
102. Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K. Possible predisposing factors for the second hip fracture. Calcif Tissue Int1998; 62:366–9.[Web of Science][Medline]
103. Grisso JA, Kelsey JL, Strom BL, Chui GY, Maislin G, O'Brien LA, Hoffman S, Kaplan F, the Northeast Hip Fracture Study Group. Risk factors for falls as a cause of hip fracture in women. N Engl J Med1991; 324:1326–31.[Abstract]
104. Saxena P, Shankar J. Contralateral hip fractures – can predisposing factors be determined? Injury Int J Care Injured2000; 31:421–4.
105. Nevitt MC, Cummings SR, the Study of Osteoporotic Fractures Research Group. Type of fall and risk of hip and wrist fractures: the Study of Osteoporotic Fractures. J Am Geriatr Soc1993; 41:1226–34.[Web of Science][Medline]
106. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med1992; 327:1637–42.[Abstract]
107. Cooper C, Barker DJP, Wickham C. Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. Br Med J1988; 297:1443–6.
108. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. Br Med J1993; 307:1111–15.
109. Lauritzen JB, Lund B. Risk of hip fracture after osteoporosis fractures. Acta Orthop Scand1993; 64:297–300.[Web of Science][Medline]
110. Gallagher JC, Melton LJ III, Rigsby L, Bergstrahl E. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop1980; 150:163–71.
111. Schröder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Rel Res1993; 289:166–69.[Medline]
112. Wand JS. Risk of refracture after removing hip fixation. J Bone Joint Surg B1990; 72:148–9.
113. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, the Study of Osteoporotic Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res1999; 14:821–8.[Web of Science][Medline]
114. Karlsson M, Nilsson JÅ, Sernbo I, Redlund-Johnell I, Johnell O, Obrant KJ. Changes of bone mineral mass and soft tissue composition after hip fracture. Bone1996; 18:19–22.[Medline]
115. Dirschl DR, Henderson RC, Oakley WC. Accelerated bone mineral loss following a hip fracture: a prospective longitudinal study. Bone1997; 20:79–82.
116. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res1994; 9:1959–66.[Web of Science][Medline]
117. Harris S, Dawson-Hughes B. Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women. Bone Miner1992; 17:87–95.[Web of Science][Medline]
118.
Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. Br Med J1994; 309:691–5.
119. Wand JS, Smith T, Green JR, Hesp R, Bradbeer JN, Reeve J. Whole body and site-specific bone remodelling in patients with previous femoral fractures. Relationships between reduced physical activity, reduced bone mass and increased bone resorption. Clin Sci1992; 83:665–75.[Medline]
120. Fatayerji D, Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res1999; 14:1203–10.[Web of Science][Medline]
121. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int1996; 59:328–33.[Web of Science][Medline]
122. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fractures in elderly women: the EPIDOS Prospective Study. J Bone Miner Res1996; 11:1531–8.[Web of Science][Medline]
123.
van Daele PLA, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JPTM, Birkenhäger JC, Pols HAP. Case-control analysis of bone resorption markers, disability and hip fracture: the Rotterdam study. Br Med J1996; 312:482–3.
124.
Hart JP, Shearer MJ, Klenerman L, Catterall A, Reeve J, Sambrook PN, Dodds RA, Bitensky L, Chayen J. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab1985; 60:1268–9.
125. Hodges SJ, Pilkington MJ, Stamp TCB, Catterall A, Shearer MJ, Bitensky L, Chayen J. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone1991; 12:387–9.[Medline]
126. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins Kl and K2 decreased in elderly women with hip fracture. J Bone Miner Res1993; 8:1241–5.[Web of Science][Medline]
127. Szulz P, Arlot M, Chapuy M-C, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone density in elderly women. J Bone Miner Res1994; 9:1591–5.[Web of Science][Medline]
128.
Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab1997; 82:719–24.
129. Slovik DM, Adams JS, Neer RM, Holick MF, Potts JT. Deficient production of 1,25-dihydroxyvitamin D3 in elderly osteoporotic patients. N Engl J Med1981; 305:372–4.[Abstract]
130. McKenna MJ. Differences in vitamin D status between countries in young adults. Am J Med1992; 93:69–77.[Web of Science][Medline]
131. Parfitt AM. Osteomalacia and related disorders. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease. San Diego, Academic Press, 1998:327–86.
132.
Parfitt AM, Gallagher JC, Heaney RP, Johnston CC, Neer R, Whedon GD. Vitamin D and bone health in the elderly. Am J Clin Nutr1982; 36:1014–31.
133. Aaron JE, Gallagher JC, Anderson J, Stasiak L, Longton EB, Nordin E, Nicholson M. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet1974; i:229–33.
134. Hoikka V, Alhava EM, Savolainen K, Parviainen M. Osteomalacia in fractures of the proximal femur. Acta Orthop Scand1982; 53:255–60.[Web of Science][Medline]
135. Lips P, Netelenbos JC, Jongen MJ, van Ginkel FC, Althuis AL, van Schaik CL, van der Vijgh WJ, Vermeiden JP, van der Meer C. Histomorphometric profile and vitamin D status in patients with femoral neck fracture. Metab Bone Dis Rel Res1982; 4:85–93.
136.
Compston JE, Vedi S, Croucher PI. Low prevalence of osteomalacia in elderly patients with hip fracture. Age Ageing1991; 20:132–4.
137. Evans RA, Ashwell JR, Dunstan CR. Lack of metabolic bone disease in patients with fracture of the femoral neck. Aust NZ J Med1981; 11:158–61.[Web of Science][Medline]
138. Wicks M, Garrett R, Vernon-Roberts B, Fazzalari N. Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck. J Bone Joint Surg Br1982; 64:319–22.
139. Wilton TJ, Hosking DJ, Pawley E, Stevens A, Harvey L. Osteomalacia and femoral neck fractures in the elderly patient. J Bone Joint Surg Br1987; 69:388–90.
140. Mallmin H, Ljunghall S, Larsson K. Biochemical markers of bone metabolism in patients with fracture of the distal forearm. Clin Orthop Rel Res1993; 295:259–63.
141. Hannon RA, Blumsohn A, Smith TWD, Eastell R. Changes in biochemical markers of bone turnover during fracture healing. Calcif Tissue Int1995; 56:483.
142. Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following ankle fracture. Osteo Int1999; 10:408–15.
143. Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int1999; 10:399–407.[Web of Science][Medline]
144. Minaire P. Immobilization osteoporosis: a review. Clin Rheumatol1989; 8(Suppl. 2): 95–103.
145. Poór G, Atkinson EJ, O'Fallon WM, Melton LJ III. Predictors of hip fractures in elderly men. J Bone Miner Res1995; 10:1990–7.
146. Jackson JA, Spiekerman AM. Testosterone deficiency is common in men with hip fracture after simple falls. Clin Res 1989; 37:131–6.
147. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc1991; 39:766–71.[Web of Science][Medline]
148. Rubenstein LZ, Robbins AS, Josephson KR, Schulman BL, Osterweil D. The value of assessing falls in an elderly population. A randomized clinical trial. Ann Intern Med1990; 113:308–16.
149. Vetter NJ, Lewis PA, Ford D. Can health visitors prevent fractures in elderly people? Br Med J1992; 304:888–90.
150.
Tinetti ME, Baker DI, McAvay G, Claus EB, Garrett P, Gottschalk M, Koch ML. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med1994; 331:821–7.
151. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet1999; 353:93–7.[Web of Science][Medline]
152. Bastow MD, Rawlings J, Allison SP. Benefits of supplementary tube feeding after fractured neck of femur: a randomised controlled trial. Br Med J1983; 287:1589–92.
153. Bonjour JP, Schurch MA, Rizzoli R. Nutritional aspects of hip fractures. Bone1996; 18(Suppl):139–44S.
154.
Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M, Vuori I. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med2000; 343:1506–13.
155. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet1993; 341:11–13.[Web of Science][Medline]
156. Ekman A, Mallmin H, Michaëlsson K, Ljunghall S. External hip protectors to prevent osteoporotic hip fractures. Lancet1997; 350:563–4.[Web of Science][Medline]
157. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev2000; CD001255.
158. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol1990; 76:290–5.[Web of Science][Medline]
159.
Recker RR, Davies M, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med1999; 130:897–904.
160.
Michaëlsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Ljunghall S, the Swedish Hip Fracture Study Group. Hormone replacement therapy and risk of hip fracture: population based case-control study. Br Med J1998; 316:1858–63.
161. Michaëlsson K, Weiderpass E, Farahmand BY, Baron JA, Persson P-G, Ziden L, Zetterberg C, Ljunghall S. Differences in risk factor patterns between cervical and trochanteric hip fractures. Osteoporos Int1999; 10:487–94.[Web of Science][Medline]
162. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med1993; 95:557–67.[Web of Science][Medline]
163.
Van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol1998; 37:87–94.
164.
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequecker J, Favus M, the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med1995; 333:1437–43.
165. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet1996; 348:1535–41.[Web of Science][Medline]
166.
Bone HG, Downs RWJ, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ, the Alendronate Elderly Osteoporosis Study Centers. Dose-response relationship for alendronate in osteoporotic elderly women. J Clin Endocrinol Metab1997; 82:265–74.
167.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y, the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med2001; 344:333–40.
168. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int1992; 51:105–10.[Web of Science][Medline]
169.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr1995; 61:1140–5.
170.
Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med1996; 124:400–6.
171. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int1995; 5:23–9.[Web of Science][Medline]
172.
Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 1998; 280:2077–82.
173. Crespo R, Revilla M, Crespo E, Villa LF, Rico H. Complementary medical treatment for Colles' fracture: a comparative, randomized, longitudinal study. Calcif Tissue Int1997; 60:567–70.[Web of Science][Medline]
174. Royal College of Physicians, Bone and Tooth Society. Osteoporosis. Clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London, Royal College of Physicians, 2000.
175. Yu W, Gluer CC, Fuerst T, Grampp S, Li J, Lu Y, Genant HK. Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Calcif Tissue Int1995; 57:169–74.[Web of Science][Medline]
176. Honkanen RJ, Honkanen K, Kröger H, Alhava E, Tuppurainen M, Saarikoski S. Risk factors for perimenopausal distal forearm fractures. Osteoporos Int 2000; 11:265–70.[Web of Science][Medline]
177. Eddy DM, Johnston CC Jr, Cummings SR, Dawson-Hughes B, Lindsay R, Melton LJ III, Slemenda CW. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int1998; 8(Suppl. 4): I–S82.
178. Report of the Advisory Group on Osteoporosis. London, Department of Health, 1994.
179. Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int1995; 5:427–32.[Web of Science][Medline]
180. Anon. Monthly Index of Medical Specialities. London, Haymarket Medical Ltd, 1997.
181.
Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol1995; 34:1167–71.
182. Torgerson DJ, Gosden T, Reid DM. The economics of osteoporosis prevention. Trends Endocrinol Metab1997; 8:236–9.[Medline]
183. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350:1047–59.[Web of Science][Medline]
184.
Wenger NK. Coronary heart disease: an older woman's major health risk. Br Med J1997; 315:1085–90.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. H. Solomon, C. Morris, H. Cheng, D. Cabral, J. N. Katz, J. S. Finkelstein, and J. Avorn Medication Use Patterns for Osteoporosis: An Assessment of Guidelines, Treatment Rates, and Quality Improvement Interventions Mayo Clin. Proc., February 1, 2005; 80(2): 194 - 202. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||